Related Experiment Video
Updated: Mar 19, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
10.4K
Design and engineering of deimmunized biotherapeutics
Karl E Griswold1, Chris Bailey-Kellogg2
1Thayer School of Engineering, Dartmouth, Hanover, NH, United States; Stealth Biologics LLC, Lyme, NH, United States.
Current Opinion in Structural Biology
|June 21, 2016
Summary
Engineering deimmunized biotherapeutics reduces harmful immune responses to protein drugs. This review highlights methods for deleting immunogenic epitopes to improve therapeutic protein safety and efficacy.
Area of Science:
- Biotechnology
- Immunology
- Drug Development
Background:
- Therapeutic proteins are advanced biologics for treating diseases.
- Antidrug immune responses pose risks like altered pharmacokinetics and loss of efficacy.
- Immune surveillance can lead to severe complications with biotherapeutics.
Purpose of the Study:
- To review technologies for engineering deimmunized biotherapeutics.
- To emphasize methods for removing immunogenic epitopes.
- To improve the safety and effectiveness of protein-based drugs.
Main Methods:
- Review of recent advancements in deimmunization technologies.
- Focus on epitope deletion via mutagenesis.
- Integration of experimental and computational approaches.
Main Results:
- Progress in engineering biotherapeutics with reduced immunogenicity.
- Successful deletion of antibody and T cell epitopes.
- Potential for enhanced drug safety and predictable pharmacokinetics.
Conclusions:
- Deimmunization technologies are crucial for next-generation protein therapeutics.
- Targeted epitope removal via mutagenesis improves biotherapeutic profiles.
- Engineered deimmunized biotherapeutics offer safer and more effective treatment options.
